Lazurite Holdings LLC, formerly Indago, recently was awarded the inaugural Accelerating the Cutting Edge Award for Innovation from the American Orthopaedic Society for Sport Medicine (AOSSM) for its ArthroFree Wireless arthroscopic camera system.
Lazurite’s Wireless Surgical Camera Wins AOSSM Award
1 min read Premium comments
#surgicalcamera#orthopedicsurgery#lazurite
The award was announced at the combined annual meeting of the American Orthopaedic Society for Sport Medicine and the Arthroscopy Association of North America.
With the company’s proprietary low heat, high intensity Meridiem light engine technology, and its advanced camera, battery, and wireless transmission technologies, it is minimally invasive.
The system is compatible with current operating room technology and was designed to not only improve operating room productivity which will cut costs, but also to enhance patient safety.
“We are tremendously excited and proud to receive this inaugural award, especially at our first exhibition of ArthroFree,” Eugene Malinskly, company chief executive officer and founder said in a statement.
“It’s very gratifying to have met with so many enthusiastic visitors at our booth. Conference attendees demoed our pre-production models of ArthroFree, met with our team, and also had the opportunity to speak directly with several physician champions who were at our booth with us.”
While not approved yet, the ArthroFree system is expected to be the first U.S. Food and Drug Administration-approved fully wireless camera system for the operating room.
Lazurite says that it plans to submit for 510(k) premarket notification in late 2021. Once it receives FDA
All products introduced since July 2020 were eligible for the ACE Award. It was open to all the exhibitors at the American Orthopaedic Society for Sport Medicine annual meeting.
Lazurite also recently announced the appointments of Scott Leube as director of business development and James Williams, M.D., as chief medical advisor.
Williams is a retired chief of orthopedic surgery at Cleveland Clinic. Leub comes from leadership roles with Zeiss Surgical, NuVasive, Inc., United States Surgical Corporation and MedAction.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.